{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:47:49Z","timestamp":1790293669336,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.japh.2019.11.008","type":"journal-article","created":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T09:56:01Z","timestamp":1576749361000},"page":"253-261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":102,"title":["Use of cannabidiol in anxiety and anxiety-related disorders"],"prefix":"10.1016","volume":"60","author":[{"given":"Jessica W.","family":"Skelley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal M.","family":"Deas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Curren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Ennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.japh.2019.11.008_bib1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrn3945","article-title":"Neuronal circuits for fear and anxiety","volume":"16","author":"Tovote","year":"2015","journal-title":"Nat Rev Neurosci"},{"issue":"3","key":"10.1016\/j.japh.2019.11.008_bib2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.psc.2009.05.004","article-title":"The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology","volume":"32","author":"Martin","year":"2009","journal-title":"Psychiatr Clin North Am"},{"issue":"6","key":"10.1016\/j.japh.2019.11.008_bib3","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/archpsyc.62.6.593","article-title":"Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"10.1016\/j.japh.2019.11.008_bib4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11920-019-1026-z","article-title":"Cannabinoid regulation of fear and anxiety: an update","volume":"21","author":"Papagianni","year":"2019","journal-title":"Curr Psychiatry Rep"},{"issue":"3","key":"10.1016\/j.japh.2019.11.008_bib5","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1517\/14728214.2015.1049996","article-title":"Emerging drugs for the treatment of anxiety","volume":"20","author":"Murrough","year":"2015","journal-title":"Expert Opin Emerg Drugs"},{"issue":"9","key":"10.1016\/j.japh.2019.11.008_bib6","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nrd4075","article-title":"50 years of hurdles and hope in anxiolytic drug discovery","volume":"12","author":"Griebel","year":"2013","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"10.1016\/j.japh.2019.11.008_bib7","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1176\/appi.ajp.2016.16030353","article-title":"Using neuroscience to help understand fear and anxiety: a two-system framework","volume":"173","author":"LeDoux","year":"2016","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1016\/j.japh.2019.11.008_bib8","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","article-title":"Cannabidiol as a potential treatment for anxiety disorders","volume":"12","author":"Blessing","year":"2015","journal-title":"Neurotherapeutics"},{"issue":"6","key":"10.1016\/j.japh.2019.11.008_bib9","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2174\/1871527313666140612114838","article-title":"Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa","volume":"13","author":"de Mello Schier","year":"2014","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"11","key":"10.1016\/j.japh.2019.11.008_bib10","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.jpsychires.2012.08.012","article-title":"Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors","volume":"46","author":"Campos","year":"2012","journal-title":"J\u00a0Psychiatr Res"},{"issue":"A","key":"10.1016\/j.japh.2019.11.008_bib11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neubiorev.2016.12.033","article-title":"The endocannabiniod system as a target for novel anxiolytic drugs","volume":"76","author":"Patel","year":"2017","journal-title":"Neurosci Biobehav Rev"},{"issue":"10","key":"10.1016\/j.japh.2019.11.008_bib12","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.tips.2009.07.006","article-title":"Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb","volume":"30","author":"Izzo","year":"2009","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.japh.2019.11.008_bib13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1089\/can.2016.0034","article-title":"An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies","volume":"2","author":"Iffland","year":"2017","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1016\/j.japh.2019.11.008_bib14","series-title":"(Cannabidiol) [Prescribing Information]","year":"2018"},{"key":"10.1016\/j.japh.2019.11.008_bib15","author":"Schiller"},{"issue":"7","key":"10.1016\/j.japh.2019.11.008_bib16","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLOS Med"},{"issue":"2","key":"10.1016\/j.japh.2019.11.008_bib17","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/sj.npp.1300340","article-title":"Effects of cannabidiol (CBD) on regional cerebral blood flow","volume":"29","author":"Crippa","year":"2004","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.japh.2019.11.008_bib18","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.biopsych.2014.08.006","article-title":"Neurobiological signatures of anxiety and depression in resting-state functional magnetic resonance imaging","volume":"77","author":"Oathes","year":"2015","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.japh.2019.11.008_bib19","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7812\/TPP\/18-041","article-title":"Cannabidiol in anxiety and sleep: A large case series","volume":"23","author":"Shannon","year":"2019","journal-title":"Perm J"},{"issue":"4","key":"10.1016\/j.japh.2019.11.008_bib20","doi-asserted-by":"crossref","first-page":"16","DOI":"10.7812\/TPP\/16-005","article-title":"Effectiveness of cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder: A case report","volume":"20","author":"Shannon","year":"2016","journal-title":"Perm J"},{"key":"10.1016\/j.japh.2019.11.008_bib21","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3389\/fphar.2017.00259","article-title":"Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life","volume":"8","author":"Zuardi","year":"2017","journal-title":"Front Pharmcol"},{"issue":"1","key":"10.1016\/j.japh.2019.11.008_bib22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2201\/nonlin.003.01.002","article-title":"The inverted \"U-shaped\" dose-effect relationships in learning and memory: modulation of arousal and consolidation","volume":"3","author":"Baldi","year":"2005","journal-title":"Nonlin Biol Toxicol Med"},{"issue":"1 Suppl","key":"10.1016\/j.japh.2019.11.008_bib23","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/026988119300700112","article-title":"Effects of ipsapirone and cannabidiol on human experimental anxiety","volume":"7","author":"Zuardi","year":"1993","journal-title":"J\u00a0Psychopharmacol"},{"issue":"1","key":"10.1016\/j.japh.2019.11.008_bib24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1590\/1516-4446-2017-0015","article-title":"Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test","volume":"41","author":"Linares","year":"2019","journal-title":"Braz J Psychiatry"},{"issue":"6","key":"10.1016\/j.japh.2019.11.008_bib25","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/npp.2011.6","article-title":"Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-na\u00efve social phobia patients","volume":"36","author":"Bergamaschi","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.japh.2019.11.008_bib26","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/0269881110379283","article-title":"Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report","volume":"25","author":"Crippa","year":"2011","journal-title":"J\u00a0Psychopharmacol"},{"issue":"3","key":"10.1016\/j.japh.2019.11.008_bib27","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/npp.2009.184","article-title":"Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology","volume":"35","author":"Bhattacharyya","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.japh.2019.11.008_bib28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archgenpsychiatry.2008.519","article-title":"Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing","volume":"66","author":"Fusar-Poli","year":"2009","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"10.1016\/j.japh.2019.11.008_bib29","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1017\/S1461145709990617","article-title":"Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol","volume":"13","author":"Fusar-Poli","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"10.1016\/j.japh.2019.11.008_bib30","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/0014-2999(74)90129-0","article-title":"Cannabidiol interferes with the effects of delta 9 - tetrahydrocannabinol in man","volume":"28","author":"Karniol","year":"1974","journal-title":"Eur J Pharmacol"},{"issue":"32","key":"10.1016\/j.japh.2019.11.008_bib31","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.2174\/138161212802884780","article-title":"Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers","volume":"18","author":"Martin-Santos","year":"2012","journal-title":"Curr Pharm Des"},{"issue":"3","key":"10.1016\/j.japh.2019.11.008_bib32","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF00432554","article-title":"Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects","volume":"76","author":"Zuardi","year":"1982","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"10.1016\/j.japh.2019.11.008_bib33","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2133\/dmpk.DMPK-11-RG-107","article-title":"Comparison in the in\u00a0vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity","volume":"27","author":"Yamaori","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"issue":"1","key":"10.1016\/j.japh.2019.11.008_bib34","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/14740338.2017.1397128","article-title":"Drug-drug interactions as a result of co-administering \u03949-THC and CBD with other psychotropic agents","volume":"17","author":"Rong","year":"2018","journal-title":"Expert Opin. Drug Saf"},{"issue":"1","key":"10.1016\/j.japh.2019.11.008_bib35","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/03602532.2013.849268","article-title":"Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review","volume":"46","author":"Stout","year":"2014","journal-title":"Drug Metab Rev"},{"issue":"B","key":"10.1016\/j.japh.2019.11.008_bib36","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.yebeh.2016.11.021","article-title":"The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.S. law","volume":"70","author":"Mead","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.japh.2019.11.008_bib37","series-title":"2015 warning letters and test results","year":"2015"},{"key":"10.1016\/j.japh.2019.11.008_bib38","series-title":"2016 warning letters and test results","year":"2016"},{"issue":"24","key":"10.1016\/j.japh.2019.11.008_bib39","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1001\/jama.2015.6613","article-title":"Cannabinoid dose and label accuracy in edible medical cannabis products","volume":"313","author":"Vandrey","year":"2015","journal-title":"JAMA"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154431911930514X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154431911930514X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:46:47Z","timestamp":1761544007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154431911930514X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S154431911930514X"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2019.11.008","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of cannabidiol in anxiety and anxiety-related disorders","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2019.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}